ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Arthritis & Rheumatology

Effect of DMARDs on Pain Sensitivity in RA

Arthritis & Rheumatology  |  December 2, 2025

Aydemir et al. examined the relationship between disease activity in rheumatoid arthritis (RA) and pain regulatory mechanisms of the central nervous system. They found that improvements in pain sensitivity were associated with reductions in disease activity in patients with RA after 12 weeks of treatment with disease-modifying anti-rheumatic drugs. This study underscores the importance of inflammatory and noninflammatory contributors to patient outcomes.

Research Reviews: AURORA 2, & Urinary Biomarkers

Arthritis & Rheumatology  |  November 25, 2025

AURORA 2 Voclosporin, a novel calcineurin inhibitor (CNI), is associated with a favorable metabolic profile with regard to lipids and glucose, and a predictable pharmacokinetic profile, resulting in no need for the therapeutic drug monitoring required of other CNIs. AURORA 2, a double-blind, phase 3 study, evaluated the longterm safety, tolerability and efficacy of voclosporin…

Autoantibodies Illuminate Lupus Nephritis

Arthritis & Rheumatology  |  November 24, 2025

In this study, Fava et al. investigated longitudinal autoantibody profiles in a racially diverse cohort of patients with lupus nephritis to define noninvasive serological biomarkers of histologic class and one-year treatment response to standard of care. In addition, the researchers determined how these biomarkers changed over time to provide further insights into treatment response and…

The Role of FGL-1 in Sjögren Disease

Arthritis & Rheumatology  |  October 29, 2025

Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.

Benefits of Early Initiation of Biologic DMARDs in pJIA

Arthritis & Rheumatology  |  October 2, 2025

The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.

Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs

Arthritis & Rheumatology  |  August 26, 2025

Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.

New Review Article Explores Endotyping, B Cells & More

Arthritis & Rheumatology  |  August 26, 2025

A case-based review examines B cells in Sjögren’s disease, the use of endotyping for patient stratification & prognostication, & lymphoma risk.

Results for Novel, Glucocorticoid-Sparing Treatment for Patients with PMR

Arthritis & Rheumatology  |  July 31, 2025

A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.

Air Pollution May Increase the Risk of RA & RA-Associated ILD

Arthritis & Rheumatology  |  June 25, 2025

Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.

Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View

Arthritis & Rheumatology  |  May 27, 2025

Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.

  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences